Browse by Author or Creator

2018

1. Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., Elsheik, S., Hadjimichael, E., Villasanti, N., Adams, S. E., Cunnell, M., Metheringham, R. L., Brentville, V. A., Machado, L., Daniels, I., Gijon, M., Hannaman, D. and Durrant, L. G. (2018) Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology. 7(6) 2162-4011.
2. Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., Elsheik, S., Hadjimichael, E., Villasanti, N., Adams, S. E., Cunnell, M., Metheringham, R. L., Brentville, V. A., Machado, L., Daniels, I., Gijon, M., Hannaman, D. and Durrant, L. G. (2018) Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology. 7(6), e1433516. 2162-4011.

2017

1. Poole, H., Sixsmith, J., Parkes, J., Ward, A., Pyer, M., Campbell, J., Machado, L., Rehling, T., Youell, J., Carter, J., Oyebode, J., O’Malley, M., Anthony, K., Rogers, S., Jones, J., Siddons, L., Smith, L.-A., Kay, A. D., Fraser, M., Score, J., El Khoury, L., Hameed, A., Albalbeisi, N., Durrant, L. G., Al-Zubaidi, R., Al-Rayahi, I., da Silva, K. and Taylor, J. (2017) Health and wellbeing amongst older people research in Northamptonshire.

2016

1. Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S. and Durrant, L. G. (2016) Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK, 06-09 November 2016.
2. Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S. and Durrant, L. G. (2016) Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, University of Birmingham, 2016-11-06 - 2016-11-09.

2014

1. Durrant, L. G., Ottensmeier, C., Lorigan, P., Mulatero, C., Plummer, R., Cunell, M., Metheringham, R. L., Brentville, V. A. and Machado, L. (2014) Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. Cancer Research. 74(19 Sup) 0008-5472.
2. Patel, P. M., Durrant, L. G., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Cunnell, M., Metheringham, R. L., Brentville, V. A., Machado, L., Daniels, I. and Hannaman, D. (2014) Phase I trial of ImmunoBody in melanoma patients. Poster presented to: 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, McCormick Place, Chicago, Illinois, 30 May - 03 June 2014. (Unpublished)
3. Durrant, L. G., Xue, L., Machado, L., Metheringham, R. L. and Brentville, V. A. (2014) DNA vaccines. In: Rees, R. C. (ed.) Tumor Immunology and Immunotherapy. Oxford: Oxford University Press. pp. 251-264.
4. Machado, L., Moseley, P., Moss, R., Nolan, C., Rampage, J., Chan, S. and Durrant, L. G. (2014) High-mobility group protein 1 (HMGB1) is an independent predictor of poor survival in ovarian cancer. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK, 02-05 November 2014. Also presented at: British Society for Immunology Annual Congress (BSI2014), Brighton, UK, 01-04 December 2014 (Unpublished)